ixekizumab
eli lilly
[' psa', ' ixe ']
#abs0380 #acr22 om1 psa cohort retro: psa pts w/comorbidities &amp;prior biologic use (both tnfi&amp;sec) respond well to ixe after 12 mo even w/monotherapy:ixe mono (82% pts) change in cdai from bl to 6 mo -3.6 points&amp; 12 mo -4.9 pts (statistically significant for both) 
Rheumatologist at Scarsdale Medical Group, Runner, Traveler Opinions are my own